Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

This study in Arabidopsis thaliana found that exposure to volatile compounds from Penicillium aurantiogriseum promotes root hair growth through signaling involving RALF22, ethylene, auxin, and photosynthesis, and that RALF22 plays a crucial role in the plants' response to these compounds.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This article discusses female pattern androgenic alopecia, emphasizing its impact on women's lives and highlighting the need for further research into effective treatments, but reports no new clinical results.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This study identifies specific molecular components involved in the intracellular trafficking of LGR5, revealing mechanisms that differ from typical GPCR recycling processes.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

This study reports three cases of alopecia areata resistant to corticosteroids that improved after 16 weeks of treatment with a combination of fractional carbon dioxide laser and topical tacrolimus, suggesting a potential new therapeutic option that requires further confirmation.

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

This study suggests that analyzing microscopic hair morphology, particularly loss of typical clubbing and proximal tapering, may help predict the clinical course of alopecia areata.

This snippet mentions an increase in women seeking surgical hair restoration and subsequently encountering more cases of frontal fibrosing alopecia, but the abstract doesn't contain results or conclusions.

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study found that dermoscopy of the axilla in patients with frontal fibrosing alopecia revealed significantly higher odds of brownish peripillary halos, suggesting a diagnostic clue for the condition in this region.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This study found that among Australians aged 15 and older, the lifetime prevalence of alopecia areata ranged from 1.2% to 2.3%, and the point prevalence ranged from 0.9% to 1.4%, emphasizing the need for better awareness and education about treatment options.

This article reviews acromegaloid facial appearance syndrome and presents a case in a 57-year-old woman, emphasizing the need for more cases to understand its clinical features and inheritance patterns.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This review covers the clinical presentation and challenges in treating frontal fibrosing alopecia in postmenopausal women and concludes that more research is needed to understand its etiology and develop effective treatments.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

This study found that alopecia areata often affects beard hair as frequently as scalp hair, leading the authors to propose a new scoring system and a subtype called alopecia subuniversalis for extensive hair involvement.

This study reports that most cases of frontal fibrosing alopecia did not show significant improvement with available treatments, and effective management remains unproven.